Fortis Healthcare Limited
FORTIS
Rank in Stocks
#3001
Established in 1996 and headquartered in Gurugram, India, Fortis Healthcare... Established in 1996 and headquartered in Gurugram, India, Fortis Healthcare Limited operates as an integrated provider of healthcare services. The company extends its offerings, which encompass secondary, tertiary, and quaternary medical care, across India, the United Arab Emirates, Sri Lanka, and other international markets. Its diverse healthcare infrastructure includes a network of hospitals, diagnostic facilities, and specialized day-care centers. Fortis delivers expertise across a broad spectrum of medical disciplines, including cardiology, cosmetic and dental sciences, dermatology, endocrinology, emergency medicine, ENT, fetal medicine, gastroenterology and hepatology, general surgery, haematology, infertility treatment, internal medicine, mental and behavioral health, nephrology, neurosurgery, neurointervention, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy, plastic surgery, pulmonology, radiology, rheumatology, thoracic surgery, transplant medicine, urology, and numerous other supporting specialties. By March 31, 2022, the company managed 26 hospitals, housing approximately 4,300 operational beds, in addition to around 426 diagnostic centers and laboratories, complemented by 2,550 collection centers.
Share Price
$8.14
Market Cap
$6.15B
Change (1 day)
-0.03%
Change (1 year)
-34.74%
Country
IN
Trade Fortis Healthcare Limited (FORTIS)
Category
Healthcare
P/E ratio for Fortis Healthcare Limited (FORTIS)
P/E ratio as of October 2026 TTM: 54.45
According to Fortis Healthcare Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 54.45. At the end of 2024 the company had a P/E ratio of 54.07.
P/E ratio history for Fortis Healthcare Limited from 2002 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 54.45 | -18.88% |
| 2025 | 67.12 | 24.12% |
| 2024 | 54.07 | 62.25% |
| 2023 | 33.33 | -15.61% |
| 2022 | 39.49 | -128.83% |
| 2021 | -136.98 | -183.33% |
| 2020 | 164.39 | -658.59% |
| 2019 | -29.43 | 259.86% |
| 2018 | -8.18 | -129.63% |
| 2017 | 27.60 | -106.07% |
| 2016 | -454.80 | 516.52% |
| 2015 | -73.77 | -243.67% |
| 2014 | 51.35 | 302.61% |
| 2013 | 12.75 | -85.73% |
| 2012 | 89.35 | 14.34% |
| 2011 | 78.14 | -53.98% |
| 2010 | 169.81 | -18.80% |
| 2009 | 209.12 | -316.02% |
| 2008 | -96.81 | 47.26% |
| 2007 | -65.74 | -41.19% |
| 2006 | -111.78 | -85.13% |
| 2005 | -751.47 | -19.81% |
| 2004 | -937.07 | 191.12% |
| 2003 | -321.88 | 17.26% |
| 2002 | -274.51 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 15.70 | -71.16% |
US
|
|
| - | - |
DE
|
|
| 10.40 | -80.90% |
US
|
|
| 32.07 | -41.10% |
SA
|
|
| 20.00 | -63.27% |
BR
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.